natgillin/translations-raw huggingface dataset:
lithium (a medicine used to treat some types of depression); medicines or substances that increase the amount of potassium in your blood.
litija (zdravila, ki se uporablja za zdravljenje nekaterih vrst depresij); zdravil ali snovi, ki zvečajo količino kalija v krvi.
Lithium (used to treat depression)
litij (uporablja se za zdravljenje depresije)
Lithium containing medicines to treat some types of depression.
Zdravila z litijem za zdravljenje nekaterih oblik depresije.
Lithium containing medicines to treat some types of depression.
Zdravila z litijem, ki se uporabljajo za zdravljenje nekaterij vrst depresije.
Lithium containing medicines to treat some types of depression.
Zdravila, ki vsebujejo litij za zdravljenje nekaterih vrst depresije.
Lithium Reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with ACE inhibitors, angiotensin II receptor antagonists including valsartan or thiazides.
valsartan in hidrokloro- tiazid litij Med sočasno uporabo litija in zaviralcev angiotenzinske konvertaze, antagonistov angiotenzinskih receptorjev tipa II, vključno z valsartanom ali tiazidov, so poročali o reverzibilnem povečanju koncentracije litija v serumu in povečanju njegovih toksičnih učinkov.
Lithium salts – for mental health problems.
Litijeve soli – za težave z duševnim zdravjem.
Lithium – used to treat depression
litij – uporablja se za zdravljenje depresije
lithium, a medicine used to treat some types of psychiatric illness.
litija, zdravila, ki ga uporabljamo za zdravljenje nekaterih vrst duševnih bolezni.
Lithium-containing medicines to treat some types of depression.
zdravila z litijem, za zdravljenje nekaterih oblik depresije,
Lithium:
Litij
Little Chalfont Buckinghamshire HP7 9NA United Kingdom
Little Chalfont Buckinghamshire HP7 9NA Velika Britanija
Little or no cytochrome P450-mediated metabolism is evident.
Znakov presnove prek sistema citokroma P450 je malo ali pa jih ni.
Live attenuated
virus stekline, živ,
Live attenuated Aujeszky’s Disease
CCID50* na odmerek.
Live attenuated Aujeszky’s disease virus
Živ, atenuiran virus Aujeszkyjeve bolezni
Live attenuated Aujeszky’s disease virus, strain NIA3-783:  105.2 CCID50* per 2 ml dose of reconstituted emulsion.
Živ, atenuiran virus Aujeszkyjeve bolezni, sev NIA3-783: 105.2. CCID50* v 2 ml odmerkih po pripravi emulzije
Live attenuated avian infectious bronchitis virus (IBV), variant strain 4-91: ≥3.6 log10 EID50 per dose
Živi, oslabljeni variantni sev virusa kužnega bronhitisa perutnine (IBV) 4-91:  3,6 log10 EID50* na odmerek
Live attenuated avian infectious bronchitis virus (IBV), variant strain 4-91:  3.6 log10 EID50*
Živi, oslabljeni variantni sev virusa kužnega bronhitisa perutnine (IBV) 4-91:  3,6 log10 EID50
Live attenuated avian infectious bronchitis virus, strain D388: 104.0 – 105.5 EID50/dose
Živi oslabljeni sev virusa infekcioznega bronhitisa perutnine D388: 104.0 - 105.5 EID50/odmerek
Live attenuated avian infectious bronchitis virus, strain D388: 104.0 – 105.5 EID501
Živi oslabljeni sev virusa infekcioznega bronhitisa perutnine D388: 104.0 – 105.5 EID501
Live attenuated infectious bronchitis virus strain 4-91  3.6 log10 EID50* per dose
Živi, oslabljeni sev virusa kužnega bronhitisa perutnine 4-91:  3,6 log10 EID50* na odmerek
Live attenuated Muscovy duck parvovirus strain GM 199 ......................
Atenuiran parvovirus rac moškatnih bleščavk, sev GM 199 ...............................
Live attenuated Muscovy duck parvovirus strain GM 199 ....................................
Atenuirani parvovirus rac moškatnih bleščavk, sev GM199..................................
Live attenuated Muscovy duck parvovirus.
Atenuiran parvovirus rac moškatnih bleščavk.
Live attenuated virus vaccines
Cepiva z živim, oslabljenim virusom
Live attenuated virus vaccines
Cepiva, pripravljena iz živih oslabljenih virusov
Live attenuated virus vaccines
Živa atenuirana virusna cepiva
Live birth
Živo rojstvo
Live birth rate*
Delež vitalnih nosečnosti
Live birth rate*
Delež živorojenih
Live deletion mutant Streptococcus equi strain TW928 109.0 to 109.4 cfu
Živi delecijski mutant seva Streptococcus equi TW928 109,0 do 109,4 CFU
Live deletion mutant Streptococcus equi strain TW928 109.0 to 109.4 cfu1 1colony forming units
Živi delecijski mutant seva Streptococcus equi TW928 109,0 do 109,4 CFU Colony forming units – kolonijske enote
Live deletion mutant Streptococcus equi strain TW928 109.0 to 109.4 cfu1 1colony forming units
Živi delecijski mutant seva Streptococcus equi TW928 109,0 do 109,4 CFU1 1 Colony forming units – kolonijske enote
Live E. coli: 5.2 x 106 to 9.1 x 108 CFU/dose
Živa E. coli 5,2 x 106 do 9,1 x 108 CFU/odmerek
Live E.coli, O8:K87.
živi sev E.coli, O8:K87.
Live feline calicivirus (strain F9) 104.6-106.1 CCID50
Živ virus mačje kalicivirus (sev F9)
Live feline panleucopenia virus (strain LR 72) 103.7-
Živ virus mačje panlevkopenije (sev LR 72)
Live feline viral rhinotracheitis virus (strain F2) 105.0-106.6 CCID50
Živ virus mačjega virusnega rinotraheitisa (sev F2)
Live gE- tk- double-gene deleted bovine herpes virus type 1 (BoHV-1), strain CEDDEL: 106.3 – 107.3 CCID50.
Živ gE- tk- Goveji Herpes Virus vrste 1 (BoHV-1) z dvojno delecijo genov, sev CEDDEL: 106.3 – 107.3 CCID50
Live gEP P tkP P double-gene deleted Bovine Herpes Virus type 1 (BoHV-1), strain CEDDEL: 10P P – 10P P CCIDR50 Rper 2 ml (gE-: deleted glycoprotein E; tk-: deleted thymidine kinase; CCID: cell culture infectious dose)
Živ gEP P tkP P Goveji Herpes Virus vrste 1 (BoHV-1) z dvojno delecijo genov, sev CEDDEL: 10P P – 10P P CCIDR50R (2 ml) (gE-: izbrisan glikoprotein E; tk-: izbrisana timidin kinaza; CCID: odmerek za infekcije celične kulture)
Live IBV, 4-91
Živi virus IB 4-91
Live myxoma vectored RHD virus strain 009: 103.0 and 106.1 FFU*
Miksoma virus, živi vektorski RHD sev 009: 103.0 in 106.1 FFU
Live non-pathogenic Escherichia coli O8:K87............................1.3∙108 to 9.0∙108 CFU1/dose
Živ nepatogeni sev Escherichia coli O8:K87............................1,3∙108 do 9,0∙108 k.e.1/odmerek
Live non-pathogenic Escherichia coli O8:K871..............1.3∙108 to 9.0∙108 CFU2/dose
Živ nepatogeni sev Escherichia coli O8:K871..............1,3∙108 do 9,0∙108 k.e.2/odmerek
Live non-pathogenic Escherichia coli O8:K87: 1.3∙108 to 9.0∙108 CFU/dose
Živ nepatogeni sev Escherichia coli O8:K871,3∙108d do 9,0∙108 k.e./odmerek
live r proble ms;
težave z jetri,
Live recombinant (CP7-E2Alf)
Živi rekombinatni (CP7_E2alf)
Live recombinant vaccine against Infectious Bursal Disease and Marek’s Disease.
Živo rekombinantno cepivo proti bolezni Gumboro in Marekovi bolezni.
Live Streptococcus equi.
Živi Streptococcus equi
Live vaccine against feline upper respiratory tract disease caused by Bordetella bronchiseptica.
Živo cepivo proti bolezni zgornjih dihalnih poti pri mačkah, ki jo povzroča Bordetella bronchiseptica
Live vaccines might carry an increased risk of clinical infection and should not be given to patients treated with Tecfidera unless, in exceptional cases, this potential risk is considered to be outweighed by the risk to the individual of not vaccinating.
Živa cepiva lahko predstavljajo večje tveganje za klinične okužbe, zato jih bolnikom, ki se zdravijo z zdravilom Tecfidera, ni dovoljeno dati, razen v izjemnih primerih, ko je to možno tveganje za posameznika večje, kot tveganje, če ne bi bil cepljen.
Live vaccines should not be given concurrently with Cosentyx (see also section 4.4).
Bolniki v času zdravljenja z zdravilom Cosentyx ne smejo prejeti živih cepiv (glejte tudi poglavje 4.4).
Live vaccines should not be given concurrently with Cosentyx.
Bolniki v času zdravljenja z zdravilom Cosentyx ne smejo prejeti živih cepiv.
Live vaccines should not be given concurrently with Enbrel.
Med zdravljenjem z zdravilom Enbrel bolnik ne sme prejeti živih cepiv.
Live vaccines should not be given concurrently with Simponi (see sections 4.4 and 4.6).
Živih cepiv ne smete dajati sočasno z zdravilom Simponi (glejte poglavji 4.4 in 4.6).
Live vaccines such as BCG should not be given to your baby within 6 months after birth.
Živih cepiv, kot je cepivo BCG, se ne sme dati dojenčkom v obdobju
Live Vaccines/therapeutic infectious agents
Živa cepiva/povzročitelji okužb v terapevtske namene
Live vaccines: you are advised to avoid being vaccinated with a type of vaccine called a live vaccine while being treated with Ilaris.
Živa cepiva: Priporočeno je, da se v času zdravljenja z zdravilom Ilaris izogibate cepljenju z vrsto cepiv, ki jih imenujemo "živa cepiva".
Live-attenuated
virus stekline, živ,
livedo reticularis, rash erythematous, rash pruritic, skin discolouration, skin discomfort
livedo reticularis, eritematozni izpuščaj, pruritični izpuščaj, razbarvanje kože, neugoden občutek na koži
Livensa 300 micrograms/24 hours transdermal patch
Livensa 300 mikrogramov/24 ur transdermalni obliž
Livensa is a thin, clear, oval patch with T001 stamped on the back.
Livensa je tanek, prozoren, ovalen obliž z napisom T001, natisnjenim na zadnji strani.
Livensa is intended for use by women up to the age of 60 years who:
Zdravilo Livensa je namenjeno ženskam, starim do 60 let, ki:
Livensa is not for use in children and adolescents.
Zdravilo Livensa ni namenjeno uporabi pri otrocih in mladostnikih.
Livensa is not recommended in naturally menopausal women.
Uporaba zdravila Livensa se ne priporoča ženskam po naravni menopavzi.
Livensa must not be used by breast-feeding women.
Doječe ženske ne smejo uporabljati zdravila Livensa.
Livensa must not be used in women who are or may become pregnant.
Zdravila Livensa ne smejo uporabljati nosečnice ali ženske, ki lahko zanosijo.
Livensa should not be used in naturally menopausal women
Zdravila Livensa se ne sme uporabljati pri ženskah po naravni menopavzi
Livensa should not be used in women on concomitant CEE
Zdravila Livensa se ne sme uporabljati pri ženskah, ki sočasno uporabljajo CEE
Livensa treatment response should be evaluated within 3-6 months of initiation, to determine if continued therapy is appropriate.
Odziv na zdravljenje z zdravilom Livensa je treba oceniti v 3–6 mesecih po začetku zdravljenja, da bi določili, ali je nadaljevanje zdravljenja primerno.
liver
žolčevodov
Liver aminotransferases
Jetrne aminotransferaze
Liver aminotransferases increase, bilirubin increase (associated with liver aminotransferase increase)
Zvišanje jetrnih aminotransferaz, zvišanje bilirubina (povezano z zvišanjem jetrnih aminotransferaz)
Liver and lung toxicity related to the previous use of amiodarone.
Toksičnimi učinki na jetra ali pljuča, povezanimi s predhodno uporabo amiodarona.
liver and pancreas problems increased fatty acids (triglycerides), bilirubin or sugar levels in the blood
težave z jetri in trebušno slinavko; povišane ravni maščobnih kislin (trigliceridov), bilirubina ali sladkorja v krvi.
liver and pancreas problems increased levels of creatinine in your blood
težave z jetri in trebušno slinavko povišanje ravni kreatinina v krvi
Liver and renal graft rejection, Vogt- Koyanagi- Harada disease
zavrnitev jetrnega in ledvičnega presadka, bolezen Vogt- Koyanagi- Harada
Liver cancer
Rak jeter
Liver cirrhosis, liver failure1
ciroza jeter, jetrna odpoved1
liver damage
jetrna okvara;
Liver damage
okvara jeter
Liver damage
Poškodbe jeter
Liver damage (hepatocellular/cholestatic
Jetrna okvara (hepatocelularna/holestats ka/mešana)
liver damage (may cause yellowing of the skin and eyes, dark coloured urine)
okvare jeter (lahko povzročijo porumenelost kože in oči, temno obarvan urin);
liver damage - this may show up in blood tests
poškodba jeter – lahko se pokaže pri krvnih preiskavah
liver damage caused by blocking of the small veins within the liver (veno-occlusive disease)
okvara jeter, ki jo povzroči zamašitev drobnih ven v jetrih (venookluzivna bolezen)
liver damage caused by blocking of the small veins within the liver (veno-occlusive disease)
poškodbe jeter zaradi zamašenih majhnih žil v jetrih (vensko-okluzivna bolezen)
liver damage caused by blocking of the small veins within the liver (veno-occlusive disease)
poškodovanje jeter zaradi blokade majhnih žil v jetrih (vensko-okluzivna bolezen)
liver damage severe pain in the upper left part of the belly (abdomen) which may be associated with fever, chills, nausea and vomiting
okvara jeter močna bolečina v zgornjem levem delu trebuha (abdomna), ki je lahko povezana z zvišano telesno temperaturo, mrzlico, navzeo in bruhanjem.
liver damage severe pain in the upper left part of the belly (abdomen) which may be associated with fever, chills, nausea and vomiting
okvara jeter močna bolečina v zgornjem levem delu trebuha (abdomna), ki jo lahko spremljajo zvišana telesna temperatura, mrzlica, slabost in bruhanje.
Liver damage, kidney failure
poškodovanje jeter, odpoved ledvic
liver damage/failure
poškodba/odpoved jeter
Liver disease appearing as yellowing of the skin and white parts of the eyes.
ki se kaže kot obarvanje kože in beločnic na rumeno,
liver disease where there is a body infection.
pri bolezni jeter pri okužbi v telesu.
liver disease,
bolezen jeter,
liver disease, severe kidney problems.
bolezen jeter, hude težave z ledvicami.
Liver disease.
Bolezen jeter.
Liver disease.
jetrno bolezen,
Liver disease.
Jetrno bolezen.
Liver disease: The safety and efficacy of saquinavir/ritonavir has not been established in patients with significant underlying liver disorders, therefore saquinavir/ritonavir should be used cautiously in this patient population.
Bolezni jeter: varnosti in učinkovitosti sakvinavirja/ritonavirja pri bolnikih z obstoječimi hudimi motnjami jetrnega delovanja niso raziskali, zato se mora sakvinavir/ritonavir pri tej populaciji bolnikov uporabljati previdno.
liver disease;
bolezen jeter,
liver disease;
bolezen jeter, ali
liver disease;
bolezen jeter;
liver disease;
bolniki z obolenji jeter;
liver disease;
z obolenji jeter,
Liver disorder
bolezni jeter
liver disorder which can occur together with yellow skin and eyes, or dark-coloured urine
bolezen jeter, ki jo lahko spremljajo rumena koža in oči ali temno obarvan urin
liver disorder which can occur together with yellow skin and eyes, or dark-coloured urine
bolezen jeter, pri kateri pride do porumenevanja kože in oči ali do temne obarvanosti urina
Liver disorder*, jaundice, hepatitis, liver failure**
bolezni jeter*, ikterus, hepatitis, odpoved jeter
Liver disordera,**, liver failurea,***
bolezni jetera,**, odpoved jetera,
Liver disordera,*, hepatitisa, liver failurea,**
bolezni jetera,*, hepatitisa, odpoved jetera,
Liver disorders
jetrne bolezni,
Liver disorders
Motnje delovanja jeter
Liver disorders (e.g., liver adenoma)
bolezni jeter (npr. adenom jeter);
Liver disorders (yellow skin, yellowing of the whites of the eyes, abnormal darkening of the urine or unexplained nausea, vomiting, tiredness and loss of appetite)
jetrne motnje (porumenelost kože, porumenelost očesnih beločnic, nenormalno temen seč ali nepojasnjena slabost v želodcu, bruhanje, utrujenost in izguba apetita)
Liver disorders (yellow skin, yellowing of the whites of the eyes, abnormal darkening of the urine or unexplained nausea, vomiting, tiredness and loss of appetite)
jetrne motnje (porumenelost kože, porumenelost očesnih beločnic, nenormalno temen urin ali nepojasnjena slabost v želodcu, bruhanje, utrujenost in izguba apetita)
Liver disorders (yellow skin, yellowing of the whites of the eyes, abnormal darkening of the urine or unexplained nausea, vomiting, tiredness and loss of appetite)
jetrne motnje (porumenelost kože, porumenelost očesnih beločnicm nenormalno temen urin ali nepojasnjena slabost v želodcu, bruhanje, utrujenost in izguba apetita)
liver disorders including blocking of a liver vein
jetrne bolezni, vključno z blokado jetrne vene
liver disorders which can occur together with yellow skin and eyes
bolezni jeter, ki jih lahko spremljajo rumena koža in oči
Liver disorders which can occur together with yellow skin and eyes
bolezni jeter, ki jih lahko spremljajo rumena koža in oči,
liver disorders which can occur together with yellow skin and eyes, or dark-coloured urine (haemolytic anaemia)
bolezni jeter, ki jih lahko spremljajo rumena koža in oči ali temno obarvan urin (hemolitična anemija)
liver disorders, such as jaundice, enlarged liver or fatty liver, inflammation (hepatitis)
težave z jetri, kot so zlatenica, povečana ali zamaščena jetra, vnetje jeter (hepatitis);
liver disorders, such as jaundice, enlarged liver or fatty liver, inflammation (hepatitis) lactic acidosis (excess lactic acid in the blood ; see the next section, ‘Other possible side effects of Trizivir’)
jetrne motnje, npr. zlatenica, povečanje jeter ali zamaščena jetra, vnetje jeter (hepatitis), laktacidoza (čezmerno kopičenje mlečne kisline v krvi; glejte naslednje poglavje, "Drugi možni neželeni učinki zdravila Trizivir"),
liver disorders, such as jaundice, enlarged liver or fatty liver, inflammation (hepatitis) lactic acidosis (excess lactic acid in the blood; see the next section, ‘Other possible side effects of combination therapy for HIV’)
motnje v delovanju jeter, kot so povečana jetra, zamaščena jetra, vnetje jeter (hepatitis),težave z jetri, kot so zlatenica, povečana ali zamaščena jetra, vnetje jeter (hepatitis), laktacidoza (čezmerno kopičenje mlečne kisline v krvi; glejte poglavje »Drugi možni neželeni učinki kombiniranega zdravljenja okužbe s HIV«),
liver disorders, such as jaundice, enlarged liver or fatty liver, inflammation (hepatitis) lactic acidosis (excess lactic acid in the blood; see the next section, ‘Other possible side effects of combination therapy for HIV’)
težave z jetri, kot so zlatenica, povečana ali zamaščena jetra, vnetje jeter (hepatitis), laktacidoza (čezmerno kopičenje mlečne kisline v krvi; glejte poglavje »Drugi možni neželeni učinki kombiniranega zdravljenja okužbe s HIV« ),
Liver disorders.
Jetrne bolezni.
liver does not work as well as it should (changes in liver enzymes) allergic reactions
motnje v delovanju jeter (sprememba vrednosti jetrnih encimov) alergijske reakcije
Liver enzyme abnormalities
Nenormalne vrednosti jetrnih encimov
Liver enzyme abnormalities and liver monitoring
Abnormalnosti jetrnih encimov in spremljanje delovanja jeter
Liver enzyme changes occur most often during dose escalation, but may occur at any time during therapy.
Spremembe jetrnih encimov se najpogosteje pojavijo med povečevanjem odmerka, vendar se lahko pojavijo kadar koli med zdravljenjem.
Liver enzyme elevations and hyperbilirubinaemia
Povišanje ravni jetrnih encimov in hiperbilirubinemija
liver enzyme increase which may have an effect on some medical tests
zvišanje ravni jetrnih encimov, kar se lahko pokaže pri nekaterih laboratorijskih preiskavah
Liver enzyme increased
zvišane vrednosti jetrnih encimov
Liver enzyme increaseda
zvišane vrednosti jetrnih encimova
Liver enzyme increaseda, weight increaseam, weight decreaseam
zvišane vrednosti jetrnih encimova, povečanje telesne maseam, zmanjšanje telesne maseam
Liver enzyme increases
zvišanje jetrnih encimov
liver enzymes elevation
zvišanje vrednosti jetrnih encimov
liver enzymes elevations
zvišanje vrednosti jetrnih encimov
liver enzymes elevations, hyperbilirubinemia, cholestasis, hepatitis hepatic injury, hepatic failure†
hiperbilirubinemija, holestaza, hepatitis poškodba jeter, odpoved jeter
Liver enzymes in hepatitis B or C co-infected patients
Jetrni encimi pri bolnikih, sočasno okuženih s hepatitisom B ali C
Liver enzymes increased (transaminases, γ-GT)
zvišana vrednost jetrnih encimov (aminotransferaze, γ-GT)
Liver enzymes should be assessed before initiation of teriflunomide therapy - every two weeks during the first 6 months of treatment, and every 8 weeks thereafter or as indicated by clinical signs and symptoms such as unexplained nausea, vomiting, abdominal pain, fatigue, anorexia, or jaundice and/or dark urine.
Jetrne encime je treba določiti pred začetkom zdravljenja s teriflunomidom, in sicer vsaka 2 tedna v prvih šestih mesecih zdravljenja in nato vsakih 8 tednov ali ob pojavu kliničnih znakov in simptomov, kot so nepojasnjena navzea, bruhanje, trebušne bolečine, utrujenost, anoreksija ali zlatenica in/ali temno obarvan urin.
Liver enzymes should be monitored in all patients receiving Ketoconazole HRA.
Pri vseh bolnikih, ki prejemajo zdravilo Ketokonazol HRA, je treba spremljati jetrne encime.
Liver enzymes: elevations of AST and ALT to greater than five times the upper limit of the normal range (ULN) were seen in 3 % of 1,008 patients treated with 600 mg of efavirenz (5-8 % after long- term treatment in study 006).
Jetrni encimi: povišanje AST in ALT na več kot petkratno zgornjo mejo normalnih vrednosti (ZMN) so opazili pri 3 % od 1.008 bolnikov, zdravljenih s 600 mg efavirenza (5–8 % po dolgotrajnem zdravljenju v študiji 006).
Liver enzymes: elevations of AST and ALT to greater than five times the upper limit of the normal range (ULN) were seen in 3 % of 1,008 patients treated with 600 mg of efavirenz (5-8 % after long-term treatment in study 006).
Jetrni encimi: povišanje AST in ALT na več kot petkratno zgornjo mejo normalnih vrednosti (ZMN) so opazili pri 3 % od 1.008 bolnikov, zdravljenih s 600 mg efavirenza (5–8 % po dolgotrajnem zdravljenju v študiji 006).
Liver enzymes: elevations of AST and ALT to greater than five times the upper limit of the normal range (ULN) were seen in 3% of 1,008 patients treated with 600 mg of efavirenz (5-8% after long- term treatment in study 006).
Jetrni encimi: povišanje AST in ALT na več kot petkratno zgornjo mejo normalnih vrednosti (ZMN) so opazili pri 3 % od 1.008 bolnikov, zdravljenih s 600 mg efavirenza (5-8 % po dolgotrajnem zdravljenju v študiji 006).
Liver enzymes: elevations of AST and ALT to greater than five times the upper limit of the normal range (ULN) were seen in 3% of 1,008 patients treated with 600 mg of efavirenz (5-8% after long- term treatment in study 006).
Jetrni encimi: povišanje AST in ALT na več kot petkratno zgornjo mejo normalnih vrednosti (ZMN) so opazili pri 3 % od 1.008 bolnikov, zdravljenih s 600 mg efavirenza (5–8 % po dolgotrajnem zdravljenju v študiji 006).
Liver enzymes: Elevations of AST and ALT to greater than five times the upper limit of the normal range (ULN) were seen in 3% of 1,008 patients treated with 600 mg of efavirenz (5-8% after long-term treatment in study 006).
Jetrni encimi: povišanje (AST) in (ALT) na več kot petkratno zgornjo mejo normalnih vrednosti (ZMN) so opazili pri 3 % od 1.008 bolnikov, zdravljenih s 600 mg efavirenza (5–8 % po dolgotrajnem zdravljenju v študiji 006).
Liver failure
odpoved jeter
Liver failure
odpoved jeter,
liver failure
odpoved ledvic
Liver failure (including fatal outcome)
jetrna odpoved (tudi s smrtnim izidom),
liver failure (the liver stops working , which may cause heavy bleeding, swelling, and breathing problems)
odpoved jeter (jetra prenehajo delovati, kar lahko povzroči hude krvavite, otekanje in težave z dihanjem)
liver failure worsening of a condition called dermatomyositis (seen as a skin rash accompanying muscle weakness)
odpoved jeter poslabšanje stanja, ki se imenuje dermatomiozitis (viden kot kožni izpuščaj, ki ga spremlja mišična šibkost)
liver failure,
odpoved jeter,
liver failure, hepatitis skin rash, which may form blisters and looks like small targets (central dark spots surrounded by a paler area, with a dark ring around the edge) (erythema multiforme), a widespread rash with blisters and peeling skin, particularly around the mouth, nose, eyes and genitals (Stevens- Johnson syndrome), and a more severe form causing skin peeling in more than 30% of the body surface (toxic epidermal necrolysis).
odpoved jeter, hepatitis kožni izpuščaj, ki lahko tvori mehurčke in izgleda kot majhne tarče (na sredini temne pike obkrožene s svetlejšim delom in s temnim krogom na robu) (multiformni eritem), široko razširjen izpuščaj z mehurčki in luščenjem kože, še posebej okoli ust, nosu, oči in v predelu spolovil (Stevens–Johnsonov sindrom) in bolj huda oblika, ki povzroči luščenje kože na več kot 30 % telesne površine (toksična epidermalna nekroliza).
liver failure, hepatitis;
odpoved jeter, hepatitis